AQR Capital Management LLC Buys 4,572 Shares of Omnicell, Inc. (NASDAQ:OMCL)

AQR Capital Management LLC increased its position in Omnicell, Inc. (NASDAQ:OMCL) by 10.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,071 shares of the company’s stock after buying an additional 4,572 shares during the quarter. AQR Capital Management LLC owned 0.11% of Omnicell worth $1,328,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. Nisa Investment Advisors LLC boosted its holdings in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares during the period. EntryPoint Capital LLC boosted its holdings in Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares in the last quarter. CWM LLC increased its position in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the period. Benjamin Edwards Inc. lifted its position in shares of Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after purchasing an additional 868 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Omnicell in the second quarter worth about $104,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Stock Down 1.9 %

OMCL stock opened at $42.12 on Friday. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $45.85. The stock has a market cap of $1.93 billion, a P/E ratio of -91.57, a PEG ratio of 46.63 and a beta of 0.83. The business’s 50-day moving average price is $42.91 and its 200-day moving average price is $33.62. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. Omnicell’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.29 earnings per share. On average, equities research analysts forecast that Omnicell, Inc. will post 0.64 EPS for the current year.

Wall Street Analyst Weigh In

OMCL has been the subject of several research reports. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday. Bank of America increased their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. lifted their price target on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Finally, Wells Fargo & Company upped their price target on Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.50.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.